# Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

> **NCT06144424** · PHASE2 · COMPLETED · sponsor: **Escient Pharmaceuticals, Inc** · enrollment: 32 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Oral EP262
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06144424
- **Lead sponsor:** Escient Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-25
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06144424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06144424, "Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06144424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*